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Abstract 
Background: 
To improve strategies for the treatment of BRAF-mutant advanced colorectal 
cancer (aCRC) patients we examined individual data from patients treated 
with chemotherapy alone in three randomised trials to identify points on the 
treatment pathway where outcomes differ from BRAF wild-types. 
 
Patients and Methods: 
2530 aCRC patients were assessed from three randomised trials. End-points 
were progression free survival (PFS), response rate (RR), disease control rate 
(DCR), post-progression survival (P-PS) and overall survival (OS). 
Treatments included first-line oxaliplatin/fluorouracil (OxFU), and second-line 
irinotecan. Clinicians were unaware of BRAF-status 
 
Results 
231 patients (9.1%) had BRAF-mutant tumours. BRAF-mutation conferred 
significantly worse survival independent of associated clinicopathological 
factors known to be prognostic. Compared with wild-type, BRAF-mutant 
patients treated with first-line OxFU had similar DCR (59.2% vs 72%; adjusted 
OR=0.76,p=0.24) and PFS (5.7 vs 6.3 months; adjusted HR=1.14, p=0.26). 
Following progression on first-line chemotherapy, BRAF-mutant patients had 
a markedly shorter P-PS (4.2 vs 9.2 months, adjusted HR=1.69,p<0.001).  
 
Fewer BRAF-mutant patients received second-line treatment (33% vs 51%, 
p<0.001), but BRAF-mutation was not associated with inferior second-line 
outcomes (RR adjusted OR=0.56, p=0.45; PFS adjusted HR=1.01, p=0.93). 
 
Significant clinical heterogeneity within the BRAF-mutant population was 
observed: a proportion (24.3%) had good first-line PFS and P-PS (both >6 
months; OS=24.0 months), however 36.5% progressed rapidly through first-
line chemotherapy and thereafter, with OS=4.7 months. 
  
Conclusions 
 
BRAF-mutant aCRC confers a markedly worse prognosis independent of 
associated clinicopathological features. Chemotherapy provides meaningful 
improvements in outcome throughout treatment lines. Post-progression 
survival is markedly worse and vigilance is required to ensure appropriate 
delivery of treatment after first-line progression.  
 
 
Key messages 
 
This is the largest study of BRAF-mutant aCRC. BRAF-mutant aCRC 
patients derive similar relative benefit from chemotherapy as wild-types; 
poor prognosis is not primarily due to chemoresistance. Instead, the point 
at which outcomes differ is following progression on first-line 
chemotherapy. BRAF-mutant aCRC patients can benefit from treatment 
breaks when stable, and from second-line chemotherapy. However 
significant clinical heterogeneity was observed within the BRAF-mutant 
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population. Efforts should be concentrated on identifying BRAF-mutant 
patients who benefit from chemotherapy, and alternative strategies tested 
for those who don’t. 
 
 
INTRODUCTION 
 
The V600E activating mutation in  BRAF (BRAF-mutant) is found in the 
tumours of 8-12% patients with advanced colorectal cancer (aCRC). BRAF-
mutant aCRC is consistently associated with poor overall survival (OS) and 
progression free survival (PFS) in case series[1] and randomised controlled 
trials (RCTs).[2] In a recent RCT of previously untreated aCRC, median OS 
was 13.4 months in BRAF-mutant patients compared with 37.1 months in 
RAS and BRAF wild-types.[3]  There is urgent need to optimise treatment 
strategies to improve outcomes in this population. 
 
The mechanism for the poor prognosis is poorly understood, and it is unclear 
at what point in the aCRC treatment pathway that BRAF-mutant outcomes 
diverge from wild-types; whilst OS is uniformly poor, less impact is seen with 
PFS compared with wild-types.[4,5] It has been hypothesised that poor 
outcomes are secondary to intrinisc chemoresistance but there is a paucity of 
data describing the outcomes of BRAF-mutant aCRC with chemotherapy 
alone, particularly beyond the first-line. This is particularly important as BRAF-
mutant patients have questionable benefit from anti-epidermal growth factor 
receptor (anti-EGFR) therapies[6] and BRAF-targeted strategies have yet to 
make clinical impact in aCRC.[7,8] 
 
Importantly previous publications have not performed careful multivariate 
analysis. This is critical as BRAF-mutant aCRC is associated with 
clinicopathological features which are themselves negative prognostic 
factors,[9] including defective mismatch repair (dMMR) status[4,10], right sided 
primary tumour location (PTL)[11] and a high incidence of peritoneal 
metastases.[12] The observed poor outcomes may instead be driven by such 
factors so it is essential to prospectively factor this into analyses of outcomes. 
Only one study has adjusted BRAF outcomes by one of these factors, dMMR, 
and found poor outcomes to be independent of this.[4]  
 
This paper provides detailed analysis of the natural history of BRAF-mutant 
aCRC to give more clarity about prognosis and an evidence base to 
quantitate the benefits of different chemotherapy strategies throughout the 
treatment pathway.  
 
In a pre-planned analysis we have examined individual patient data from three 
RCTs to identify points on the treatment pathway at which BRAF-mutant 
outcomes differ from BRAF wild-type patients treated with cytotoxic 
chemotherapy, to assess the impact of potential confounders and to provide 
clinicians with detailed information of outcomes with various chemotherapy 
strategies. We analysed treatment outcomes in two first-line RCTs with 
oxaliplatin/fluorouracil (OxFU), behaviour during chemotherapy-free intervals 
and following disease progression. We then report patterns of, and outcomes 
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with second-line therapy. In order to avoid potential interactions of BRAF 
status with anti-EGFR drugs we focus on patients treated in arms that did not 
include targeted therapies. Potential confounding factors were prospectively 
identified, and analyses adjusted accordingly. BRAF-status was unknown to 
clinicians treating patients in each trial, eliminating potential bias. 
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PATIENTS AND METHODS: 
 
Patient population and treatment: 
 
Individual patient data were obtained from selected arms of three large 
randomised trials, to reflect different clinical uses of standard cytotoxic 
chemotherapy (without targeted therapy) in aCRC (Figure 1).  
 FOCUS (ISRCTN 79877428) was a sequencing trial of first-line and 
planned second-line therapy, and provided a cohort of 430 patients 
receiving single-agent 5FU ahead of planned second-line irinotecan or 
oxaliplatin-based therapy, plus a cohort of 357 randomised to first-line 
doublet (IrFU or OxFU).[13] 
 COIN (ISRCTN 27286448) provided a cohort of 1284 patients 
randomised to first-line oxaliplatin/fluoropyrimidine (OxFp) doublet 
either continuously (Arm A) or with planned chemotherapy-free 
intervals (Arm C).[14,15] 
 PICCOLO (ISRCTN 93248876) provided a cohort of 511 OxFp-
resistant patients treated with second-line irinotecan.[16,17]  
Inclusion criteria for FOCUS and COIN were consistent and both patient 
groups were treated in centres in the UK. Full reports of these studies have 
been published.[9,17-20] National ethical approval and patient consent was 
obtained for all aspects of the clinical and translational research. DNA 
extraction and genotyping for mutations including BRAFV600E was performed 
retrospectively as previously reported.[16,18,19] 
 
Statistical analysis 
 
Stata was used (Release 12 (2011), StataCorp. College Station, Texas). 
Baseline patient characteristics were compared between BRAF-mutant 
patients (with or without other MEK/AKT pathway mutations) and BRAF wild-
type patients using two-tailed T-tests, Wilcoxon rank sum tests (for variables 
with non-normally distributed frequency distributions) and Pearson Chi-
squared tests (for categorical variables). 
 
In addition to OS (time from randomisation to death from any cause), three 
treatment-related clinical endpoints were used: PFS (time from randomisation 
to first evidence of progression or death); 12-week RECIST response rate 
(RR), and disease control rate (DCR).[20] Finally, we compared post-
progression survival time (P-PS), defined as time from progression to death in 
those with a progression event, however when date of progression data was 
unavailable date of last chemotherapy cycle was used instead.   
 
The prognostic influence of BRAF-mutant status on survival outcomes (PFS, 
P-PS and OS) for first-line trials (FOCUS and COIN), then the second-line trial 
(PICCOLO) were analysed using Cox proportional hazards modelling and 
described using hazard ratios (HRs) and 95% confidence intervals (CIs), 
adjusted for factors known to be prognostic or likely to interact with BRAF-
status.  In COIN and FOCUS these were: WHO performance status (2 vs 0/1); 
primary tumour resected (yes vs no); PTL (right colon vs other); platelet count 
(< vs ≥ 400,000/μl); peritoneal metastases (present vs absent) and mismatch 
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repair (MMR) status. In PICCOLO, adjustment was made for: response to 
previous therapy; performance status; peritoneal metastases; primary tumour 
resected and PTL. As these factors individually interact with prognosis, 
adjusted values are reported primarily but unadjusted values are provided. 
 
Kaplan-Meier (KM) curves were plotted. For response endpoints, odds ratios 
(ORs) and 95% CIs were estimated from logistic regression models for the 
effect of BRAF-mutant status, adjusted for the markers previously described. 
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RESULTS 
 
Clinicopathological variables associated with BRAF-mutant aCRC  
BRAF status was available for 787/2135 (36.9%) patients in FOCUS, 
1284/1630 (78.8%) in COIN and 459/511 (89.8%) in PICCOLO (Figure 1). 
The BRAF-mutant prevalence was consistent with published values (FOCUS 
61/787 [7.8%], COIN 130/1284 [10.1%], PICCOLO 40/459 [8.7%]). BRAF-
mutant patients were more likely than wild-types to be female, have right-
sided PTL, have peritoneal or nodal metastases, but less likely to have lung 
metastases. BRAF-mutant tumours were more likely to have dMMR than wild-
type tumours (12.6% vs 3.0%, p<0.001). 8/2530 (0.3%) patients’ tumours had 
dual mutations in both BRAF and KRAS (Table 1) 
 
 BRAF-status as a prognostic marker for overall survival 
 
BRAF-mutant status was a significant prognostic marker for OS in both first-
line studies (COIN 9.8 vs 16.6 months, unadjusted HR =1.78 [1.46-2.17], 
p<0.001; FOCUS 10.9 vs 16.2 months, unadjusted HR=1.55 [1.18-2.04], 
p=0.030)(Table 2). Combining these data [n=2071] gave a median OS of 10.8 
vs 16.4 months (HR=1.49 [1.23-1.80] p<0.001)(Figure 2). 
 
As BRAF-mutant status was associated with clinicopathological 
characteristics that may interact with survival (Table 1), their prognostic 
impact was explored in a univariate, then multivariate analysis in data pooled 
from the first-line trials. Significant factors predicting poor OS on univariate 
testing were BRAF-mutant status, poor performance status, high platelet 
count, right PTL, peritoneal metastases, primary tumour in-situ and dMMR 
status; in multivariate testing, all factors remained significant other than 
dMMR status (Supplementary Table 1). 
 
Following adjustment, BRAF-mutant status remained a significant prognostic 
marker in both trials (COIN adjusted HR =1.51 [1.19-1.91], p<0.001; FOCUS 
adjusted HR=1.44 [1.04-2.00], p=0.030)(Table 2). Given the demonstrated 
prognostic effect of clinicopathological factors associated with BRAF-mutant 
status all subsequent analyses are adjusted. 
 
There was no evidence that BRAF-mutant patients had inferior OS with a 
planned treatment break when first-line treatment has not yet failed. COIN, 
which compared continuous or intermittent chemotherapy strategies, found 
that intermittent chemotherapy in the entire population was non-inferior for OS 
(adjusted HR=1.04 [0.98–1.10], p=0.16).[19] In BRAF-mutant patients this was 
also the case (adjusted HR=0.97 [0.80–1.17], p=0.75) (Supplementary Figure 
1). 
 
OS was improved in COIN for those who received subsequent second-line 
chemotherapy compared with those without, regardless of BRAF-status 
(BRAF-mutant 16.1 vs 7.8 months [HR=0.56, p=0.005]; wild-type 21.1 vs 11.6 
months [HR=0.48, p<0.001]; interaction p=0.66). However BRAF-mutant 
patients had worse OS whether treated with second-line chemotherapy, 
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(HR=1.91[1.36-2.69], p<0.001), or not (HR=1.44 [1.12-1.84], p=0.004), 
compared with wild-types. 
 
The impact of BRAF-status on OS for the 459 patients treated with second-
line irinotecan was examined in the PICCOLO trial. Whilst OS was shorter for 
BRAF-mutant patients compared with BRAF wild-type, the difference did not 
reach statistical significance: 6.7 vs 10.2 months (adjusted HR=1.21 [0.84-
1.76], p=0.31)(Supplementary Table 2 and Supplementary Figure 2). 
 
Impact of BRAF-status on chemotherapy outcomes: progression free 
survival, response rates and disease control rates. 
 
In contrast to its marked effect on OS, BRAF-mutant status had modest or 
insignificant impact on the first-line PFS and response endpoints. Although for 
patients treated with first-line OxFP in COIN  BRAF-mutant patients had an 
inferior 12-week RR (34.3% vs 47.5%, adjusted OR=0.58 [0.37-0.92], 
p=0.020), the differences in DCR and PFS were not significant (DCR 59.2% 
vs 72.0%, adjusted OR=0.76 [0.49-1.20], p=0.24; PFS 5.7 vs. 6.3 months, 
adjusted HR=1.14 [0.91-1.42], p=0.26)(Table 2). There was no evidence of a 
differential effect of BRAF status according to the doublet used (OxFU or 
OxCap)(data not shown).  
 
Similarly for patients treated with first-line combination chemotherapy in 
FOCUS, there were no differences in efficacy endpoints in BRAF-mutant 
compared with BRAF wild-type patients: PFS was 8.2 vs 8.8 months (adjusted 
HR=1.07 [0.69-1.67], p=0.75); RR was 43.7% vs 43.1% (adjusted OR=1.09 
[0.45-2.65], p=0.85); DCR was 68.9% vs 69.9% (adjusted OR=1.01 [0.36-
2.84], p=0.97)(Table 2). There was no evidence of a differential effect of 
BRAF-status according to regimen used (OxFU or IrFU, p=0.26). With first-
line single agent 5FU in this trial (n=430), PFS was similar in BRAF-mutant 
and BRAF-wt patients (6.5 vs 6.7 months; adjusted HR=0.96 [0.60-1.52], 
p=0.30); RR was 17.2% vs 21.7% (adjusted OR=0.54 [0.17,1.72], p=0.30); 
DCR 48.3% vs 60.6% (adjusted OR=0.72 [0.27-1.94], p=0.52)(Supplementary 
Table 2). 
 
We examined the impact of chemotherapy-free intervals on PFS in BRAF-
mutant patients in COIN. In all patients progression events in patients during 
chemotherapy breaks led to shorter PFS (adjusted HR=1.27 [1.21–1.33], 
p<0.001).[19] BRAF-mutant patients were the only molecular sub-group not to 
have a PFS disadvantage with intermittent chemotherapy (BRAF-mutant PFS 
adjusted HR=1.09 [0.91–1.31], p=0.33; BRAF wild-type PFS adjusted 
HR=1.29 [1.21–1.37], p<0.001; interaction p=0.14)(Supplementary Figure 1).   
 
For patients treated with second-line single-agent irinotecan in PICOLLO 
there were no significant differences between BRAF-mutant to wild-type 
patients in PFS (3.5 vs 4.0 months, adjusted HR=1.01 [0.69-1.49], p=0.93), 
RR (5.0% vs. 8.1%, adjusted OR=0.56 [0.13-2.49], p=0.45)) and DCR (42.5% 
vs. 47.7% (adjusted OR=0.82[0.41-1.62],p=0.57)(Supplementary Table 2). 
 
Impact of BRAF-status on post-progression survival 
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Following progression on first-line combination chemotherapy, BRAF-mutant 
patients had markedly reduced P-PS compared with wild-types in both first-
line trials. In COIN PPS was 3.2 months in BRAF-mutant compared with 8.6 
months in wild-type patients (adjusted HR=1.72 [1.35-2.19], p<0.001). 
Similarly in FOCUS inferior P-PS was observed between BRAF-mutant and 
wild-types (3.2 vs 8.1 months; adjusted HR=1.65 [1.03-2.67], p=0.038)(Table 
2). Combining this data P-PS was inferior in the BRAF-mutant compared with 
the BRAF-wt group (3.2 vs 8.6 months, HR=1.72 [1.35-2.19], p<0.001)(Figure 
3).  These marked differences were independent of first-line treatment 
received (in COIN, OxFU vs OxCap p=0.53, in FOCUS OxFU vs IrFU 
p=0.91)(data not shown). Finally, following progression on single-agent 5FU, 
PPS was reduced in the BRAF-mutant group (3.5 vs 9.3 months; adjusted HR 
= 2.19[1.30-3.69],p=0.003)(Supplementary Table 2), 
 
When other prognostic factors were tested in a combined multivariate model, 
a significant negative effect on P-PS was seen after first-line chemotherapy 
for peritoneal metastases and dMMR status (peritoneal metastases HR=1.39, 
p<0.0001; dMMR HR=1.38, p=0.025). However the negative prognostic 
impact of peritoneal metastases and dMMR appears limited to the BRAF wild-
type population, and neither factor impacted further on the poor P-PS seen in 
BRAF-mutant patients (interaction p= 0.005 and p=0.05 respectively), 
suggesting that it is the BRAF-mutation driving the observed poor outcomes 
(Supplementary Table 3). 
 
To explore the mechanism for inferior first-line P-PS in BRAF-mutant patients, 
we studied uptake of post-progression therapies.In COIN, BRAF-mutant 
patients were less likely to receive second-line therapy after first-line 
progression (33% vs. 51%, p=0.0002). Similarly, after completion of the 
FOCUS plan, which for all patients included two drugs (FU and either 
oxaliplatin or irinotecan, given over 1 or 2 lines), 123/401 (30.7%) BRAF wild-
type and 3/29 (10.3%) BRAF-mutant patients received subsequent salvage 
therapy (p=0.020)(data not shown).  The duration of second-line therapy 
(regimens including FU-based, Ir-based, oxaliplatin-based, cetuximab and 
bevacizumab) for those who received it, was unaffected by BRAF-mutant 
status (COIN p=0.55, FOCUS p=0.18). The only exception was the subgroup 
of FOCUS patients randomised to receive IrFU after progression on FU alone, 
where BRAF-mutant status was associated with shorter treatment duration 
(p=0.019)(data not shown).  
 
We then performed an exploratory analysis to ascertain whether the reduction 
in P-PS in BRAF-mutant patients was due to rapid progression after initial 
first-line benefit, rapid progression in patients who also rapidly progressed 
through first-line treatment, or both. Table 3 shows the breakdown of patients 
by mutational status into 4 groups depending upon duration of first-line PFS 
and subsequent P-PS: good PFS/ P-PS defined as greater than 6 months, 
poor PFS/P-PS defined as less than 6 months. Populations were therefore 
good first-line PFS and good P-PS, good first-line PFS and poor P-PS, poor 
first-line PFS and good P-PS, and finally poor PFS and poor P-PS. 
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Fewer BRAF-mut patients had good first-line PFS and good P-PS compared 
with wild-type patients (24.3% vs 39.3%, p<0.001). Conversely there was a 
significantly higher proportion of BRAF-mutant patients with very poor 
outcomes (both less than 6 months first-line PFS and P-PS) compared with 
wild-type patients (36.5% and 21.9% respectively, p<0.001). Thus, around a 
third of BRAF-mutant patients not only fail to obtain useful benefit from first-
line therapy but also rapidly progress thereafter. Of note, the difference in 
median survival of BRAF-mutant patients between these 2 groups is 24.0 
months to 4.7 months. There were no significant differences in patient 
demographics between these 2 groups; however there was a trend towards 
lower median age in the poor PFS/P-PS compared with the good PFS/P-PS 
group (61.9 vs 65.2, p=0.07). 
 
Further difference in treatment patterns were observed: 67.5% of BRAF wild-
type patients with good initial PFS also had a good P-PS compared with 
48.4% of the BRAF-mutant patients (p<0.001). Whilst 47.4% of BRAF wild-
type patients in spite of an initial poor first-line PFS went onto have a greater 
than 6 months P-PS this was the case in just 26.6% of BRAF-mutant patients.  
 
BRAF-mutant patients treated with anti-EGFR agents 
 
The benefit of the addition of anti-EGFR agents to chemotherapy in COIN and 
PICCOLO in KRAS wild-type patients has been previously reported.[9,18] 
BRAF-mutant patients treated with anti-EGFR agents had consistently inferior 
outcomes than RAS wild-type patients in both trials. 
 
When including patients treated with anti-EGFR agents, and limiting to the 
RAS wild-type population, BRAF-mutant patients had markedly worse 
outcomes. Within COIN BRAF-mutant status was associated with inferior OS 
(7.2 vs 19.9 mths, HR=2.96[1.93-4.53], p<0.001), PFS (4.8 vs 9.3mths, 
HR=1.84[1.23-2.75], p=0.003), and P-PS (1.9 vs 9.7 mths, HR=3.12 [2.14-
4.54], p<0.001). Similarly in PICCOLO BRAF-mutant patients had inferior OS 
(4.4 vs 11.1mths, HR=2.31[1.61-3.33],p<0.001), PFS (2.7 vs 5.5 mths, 
HR=1.70[1.24-2.61], p=0.002) and P-PS (3.2 vs 6.0 mths, HR=1.83[1.24-
2.61], p=0.002)(data not shown). 
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DISCUSSION 
 
This is the largest and most comprehensive clinical series assessing the 
outcomes of BRAF-mutant patients treated with chemotherapy at different 
points of the aCRC pathway. The poor outcomes of advanced BRAF-mutant 
aCRC are well described, but these cancers are associated with specific 
clinicopathological features: older age, right-sided primary tumour, high grade, 
deficient MMR, mucinous histology and peritoneal and lymph node 
metastases,[4,9-12] most of which interact with prognosis. In a careful 
multivariate analysis in a large, prospectively gathered cohort, BRAF-mutation 
still conferred a worse prognosis and is not simply attributable to associated 
clinico-pathological features.  
 
Within this dataset the poor outlook is not driven by chemoresistance. We 
observed no difference in the adjusted PFS or DCR between BRAF-mutant 
and wild-type patients receiving first-line chemotherapy. There was also no 
difference in adjusted PFS or DCR between BRAF-mutant and wild-type 
patients who received second-line irinotecan monotherapy. Results were 
consistent between both first-line trials, independent of chemotherapy strategy 
and other standard prognostic factors. OxFU is a commonly used first-line 
therapy in aCRC, and was the first-line regimen used in the majority of 
patients analysed herein, and indeed oxaliplatin may provide particular 
benefits in BRAF-mutant patients [3, 21].  
 
Our analyses suggest instead that the point at which outcomes markedly 
diverge between BRAF-mutant and wild-types is following progression on or 
after benefit from first-line chemotherapy. Further investigation suggested that 
the observed significantly worse P-PS compared with wild-types may be due 
to the combined impact of two distinct patterns. Firstly BRAF-mutant patients 
were more likely to rapidly progress through first-line therapy and then 
subsequently rapidly deteriorate, either too unfit to receive subsequent 
treatment or progressing through that therapy. Secondly, BRAF-mutant 
patients with an initial good outcome on first-line chemotherapy were more 
likely to rapidly progress thereafter. Whilst around two-thirds of wild-type 
patients with good outcomes on initial therapy subsequently survive more 
than 6 months after progression on first-line chemotherapy this fell to half of 
BRAF-mutant patients. 
 
Although, the study is limited by relative small numbers of BRAF-mutant 
patients compared to wild-types and findings should be interpreted with 
caution particularly sub-group analyses, the data suggests that a significant 
proportion of BRAF-mutant patients can obtain meaningful benefit from 
chemotherapy. Thus uniform nihilism about the impact of chemotherapy in 
deflecting the natural history of BRAF-mutant aCRC is unjustified. 
Furthermore, BRAF-mutant patients with disease control can be appropriately 
counselled about the safety of chemotherapy free intervals even though 
caution is required in the interpretation of this sub-set analysis. However, 
post-progression survival after first-line progression is clearly worse in BRAF-
mutant patients and fewer receive second-line therapy. It is important to 
emphasise that treating physicians were unaware of BRAF-status, so this 
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latter finding is not due to selection bias.  Thus, we suggest that extra 
vigilance is required when treating BRAF-mutant patients, to promptly detect 
initial progression and then rapidly institute second-line therapy in the 
knowledge that this has the capacity to significantly improve survival.  
 
A third of BRAF-mutant patients rapidly progress on and then after first-line 
therapy with no obvious benefit from chemotherapy. These patients drive 
much of the observed poor outcomes of BRAF-mutant aCRC and such 
aggressive clinical behaviour is what clinicians often have in mind when 
thinking about BRAF-mutant aCRC patients.. A biomarker is required to 
identify such patients who might benefit from an alternative therapeutic 
strategy, such as targeted therapy. The combination of a BRAF-inhibitor 
dabrafenib, a MEK inhibitor trametinib and an anti-EGFR agent panitumumab 
demonstrated an unconfirmed response rate of 30%.[22]  
 
Recent transcriptional analyses have sub-divided BRAF-mutant aCRC into 2 
sub-types with widely differing biology.[23] BM1 tumours constitute one-third of 
BRAF-mutant cancers and are characterised by enrichment of a KRAS 
signature and sensitivity to BRAF and MEK inhibition. The other two-thirds of 
BRAF-mutant aCRC, the BM2 sub-type, are characterised by accelerated 
G2/M phase with low ATM with sensitivity to cdk1 inhibition. These checkpoint 
abnormalities could contribute to chemosensitivity by preventing DNA damage 
being repaired prior to mitosis. Thus, application of these signatures to these 
two clinically divergent groups of BRAF-mutant patients appears warranted. 
Furthermore MMR testing should be encouraged in BRAF-mutant aCRC 
patients and entry into RCT testing immunotherapy agents where available. 
 
This, the largest and most comprehensive analysis of chemotherapy 
outcomes in BRAF-mutant CRC patients provides new and important 
information with clinical relevance. In summary, BRAF-mutation confers a 
markedly worse prognosis independent of associated clinicopathological 
features. However, in some patients chemotherapy does provide meaningful 
improvements in outcome throughout treatment lines and translational efforts 
need to be made to identify them and those who appear to derive no benefit 
from chemotherapy. Post-progression survival is worse in BRAF-mutant 
patients and vigilance is required to ensure the appropriate delivery of 
treatment after first-line progression. 
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Legend to Figures 
 
Figure 1- Consort diagram of study participants from the FOCUS, COIN and 
PICCOLO trials 
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Figure 2 –OS KM curves for BRAF-mut vs BRAF-wt for first line 
chemotherapy (FOCUS and COIN, all strategies) 
 
Figure 3 - Post-progression survival KM curves for BRAF-mut vs BRAF-wt 
following failure on first-line chemotherapy (COIN and FOCUS) 
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